Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs

Reuters04-01

Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs

Rezolute highlighted ersodetug (RZ358) as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism.
Phase 3 sunRIZE study in congenital hyperinsulinism did not meet primary endpoint or key secondary glucose endpoints, with up to 45% reduction in hypoglycemia events in treated groups versus 40% on placebo.
Safety profile showed no limiting findings, with early discontinuations tied to 2 serious hypersensitivity reactions.
Pipeline timeline flagged 2H 2026 for tumor hyperinsulinism Phase 3 topline data.
Liquidity update cited $133 million cash with runway to mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624656813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624656813","market":"fut","top_or_hot":-1,"title":"Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Rezolute highlighted ersodetug (RZ358) as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism.\n        </li>\n<li>\n          Phase 3 sunRIZE study in congenital hyperinsulinism did not meet primary endpoint or key secondary glucose endpoints, with up to 45% reduction in hypoglycemia events in treated groups versus 40% on placebo.\n        </li>\n<li>\n          Safety profile showed no limiting findings, with early discontinuations tied to 2 serious hypersensitivity reactions.\n        </li>\n<li>\n          Pipeline timeline flagged 2H 2026 for tumor hyperinsulinism Phase 3 topline data.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LQDT\">Liquidity</a> update cited $133 million cash with runway to mid-2028.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 10:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Rezolute highlighted ersodetug (RZ358) as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism.\n        </li>\n<li>\n          Phase 3 sunRIZE study in congenital hyperinsulinism did not meet primary endpoint or key secondary glucose endpoints, with up to 45% reduction in hypoglycemia events in treated groups versus 40% on placebo.\n        </li>\n<li>\n          Safety profile showed no limiting findings, with early discontinuations tied to 2 serious hypersensitivity reactions.\n        </li>\n<li>\n          Pipeline timeline flagged 2H 2026 for tumor hyperinsulinism Phase 3 topline data.\n        </li>\n<li>\n          <a href=\"https://laohu8.com/S/LQDT\">Liquidity</a> update cited $133 million cash with runway to mid-2028.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6knwQd:1","article_id":"2624656813","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624656813","pubTimestamp":1775009581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rezolute highlighted ersodetug  as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism.Phase 3 sunRIZE study in congenital hyperinsulinism did not meet primary endpoint or key secondary glucose endpoints, with up to 45% reduction in hypoglycemia events in treated groups versus 40% on placebo.Safety profile showed no limiting findings, with early discontinuations tied to 2 serious hypersensitivity reactions.Pipeline timeline flagged 2H 2026 for tumor hyperinsulinism Phase 3 topline data.Liquidity update cited $133 million cash with runway to mid-2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"Rezolute发布关于ERSODETUG 3期高胰岛素血症项目的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs\n    \n\n\n          Rezolute highlighted ersodetug (RZ358) as a late-stage antibody program targeting hypoglycemia across congenital hyperinsulinism and tumor-driven hyperinsulinism.\n        \n\n          Phase 3 sunRIZE study in congenital hyperinsulinism did not meet primary endpoint or key secondary glucose endpoints, with up to 45% reduction in hypoglycemia events in treated groups versus 40% on placebo.\n        \n\n          Safety profile showed no limiting findings, with early discontinuations tied to 2 serious hypersensitivity reactions.\n        \n\n          Pipeline timeline flagged 2H 2026 for tumor hyperinsulinism Phase 3 topline data.\n        \n\nLiquidity update cited $133 million cash with runway to mid-2028.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624656813","isCrawlerRequest":true}